After a month and a half initial public offering drought, two biopharmaceutical companies – Neumora Therapeutics, Inc. and RayzeBio, Inc. – launched IPOs in the US and grossed $561m combined on 14 September, in two of the largest first-time offerings this year.
Neumora sold 14.7 million shares at $17 each to gross $250m, which was in the middle of a proposed $16 to $18 price range. RayzeBio grossed $311m from the sale...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?